DK17093D0 - Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder - Google Patents

Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder

Info

Publication number
DK17093D0
DK17093D0 DK93170A DK17093A DK17093D0 DK 17093 D0 DK17093 D0 DK 17093D0 DK 93170 A DK93170 A DK 93170A DK 17093 A DK17093 A DK 17093A DK 17093 D0 DK17093 D0 DK 17093D0
Authority
DK
Denmark
Prior art keywords
pct
vaccines
mammals
antigants
miles
Prior art date
Application number
DK93170A
Other languages
English (en)
Inventor
Sveinbjoern Gizurarson
Iver Heron
Original Assignee
Lyfjathroun H F
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyfjathroun H F, Statens Seruminstitut filed Critical Lyfjathroun H F
Priority to DK93170A priority Critical patent/DK17093D0/da
Publication of DK17093D0 publication Critical patent/DK17093D0/da
Priority to PCT/DK1994/000062 priority patent/WO1994017827A1/en
Priority to DK94907503T priority patent/DK0682528T3/da
Priority to PT94907503T priority patent/PT682528E/pt
Priority to EP94907503A priority patent/EP0682528B1/en
Priority to DE69425427T priority patent/DE69425427T2/de
Priority to AU61065/94A priority patent/AU668290B2/en
Priority to JP6517549A priority patent/JPH09508614A/ja
Priority to US08/501,112 priority patent/US5942237A/en
Priority to ES94907503T priority patent/ES2150982T3/es
Priority to CA002156084A priority patent/CA2156084A1/en
Priority to AT94907503T priority patent/ATE195077T1/de
Priority to OA60698A priority patent/OA10564A/en
Priority to NO19953182A priority patent/NO312057B1/no
Priority to GR20000402416T priority patent/GR3034727T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK93170A 1993-02-15 1993-02-15 Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder DK17093D0 (da)

Priority Applications (15)

Application Number Priority Date Filing Date Title
DK93170A DK17093D0 (da) 1993-02-15 1993-02-15 Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
AT94907503T ATE195077T1 (de) 1993-02-15 1994-02-14 Ein pharmazeutisches präparat zur topischen verabreichung von antigenen und/oder vakzinen an die schleimhäute von säugern
AU61065/94A AU668290B2 (en) 1993-02-15 1994-02-14 A pharmaceutical composition for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
US08/501,112 US5942237A (en) 1993-02-15 1994-02-14 Pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
PT94907503T PT682528E (pt) 1993-02-15 1994-02-14 Uma preparacao farmaceutica para administracao topica de antigenios e/ou vacinas a mamiferos via uma membrana mucosa
EP94907503A EP0682528B1 (en) 1993-02-15 1994-02-14 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
DE69425427T DE69425427T2 (de) 1993-02-15 1994-02-14 Ein pharmazeutisches präparat zur topischen verabreichung von antigenen und/oder vakzinen an die schleimhäute von säugern
PCT/DK1994/000062 WO1994017827A1 (en) 1993-02-15 1994-02-14 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
JP6517549A JPH09508614A (ja) 1993-02-15 1994-02-14 哺乳動物に対する抗原類および／またはワクチン類の粘膜を介した局所投与のための医薬調製物
DK94907503T DK0682528T3 (da) 1993-02-15 1994-02-14 Lægemiddelpræparat til topisk administration af antigener og/eller vacciner til pattedyr via en slimhindemembran
ES94907503T ES2150982T3 (es) 1993-02-15 1994-02-14 Composicion farmaceutica para la administracion topica de antigenos y/o vacunas a mamiferos a traves de una membrana mucosa.
CA002156084A CA2156084A1 (en) 1993-02-15 1994-02-14 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane
OA60698A OA10564A (en) 1993-02-15 1995-08-11 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via amucosal membrane
NO19953182A NO312057B1 (no) 1993-02-15 1995-08-14 Farmasöytisk preparat for topisk administrering av antigener og/eller vaksiner til pattedyr via en slimhinnemembran, samtanvendelse av adjuvant
GR20000402416T GR3034727T3 (en) 1993-02-15 2000-10-30 A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK93170A DK17093D0 (da) 1993-02-15 1993-02-15 Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder

Publications (1)

Publication Number Publication Date
DK17093D0 true DK17093D0 (da) 1993-02-15

Family

ID=8090567

Family Applications (2)

Application Number Title Priority Date Filing Date
DK93170A DK17093D0 (da) 1993-02-15 1993-02-15 Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
DK94907503T DK0682528T3 (da) 1993-02-15 1994-02-14 Lægemiddelpræparat til topisk administration af antigener og/eller vacciner til pattedyr via en slimhindemembran

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK94907503T DK0682528T3 (da) 1993-02-15 1994-02-14 Lægemiddelpræparat til topisk administration af antigener og/eller vacciner til pattedyr via en slimhindemembran

Country Status (14)

Country Link
US (1) US5942237A (da)
EP (1) EP0682528B1 (da)
JP (1) JPH09508614A (da)
AT (1) ATE195077T1 (da)
AU (1) AU668290B2 (da)
CA (1) CA2156084A1 (da)
DE (1) DE69425427T2 (da)
DK (2) DK17093D0 (da)
ES (1) ES2150982T3 (da)
GR (1) GR3034727T3 (da)
NO (1) NO312057B1 (da)
OA (1) OA10564A (da)
PT (1) PT682528E (da)
WO (1) WO1994017827A1 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316745D0 (en) * 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
AU712819B2 (en) * 1996-01-25 1999-11-18 Profylakse Aps Pharmaceutical composition comprising serum amyloid P component for proph ylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components
IS4518A (is) 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
BR9909915A (pt) * 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
US7229621B2 (en) * 1998-10-20 2007-06-12 Torrey Pines Institute For Molecular Studies Method to enhance the immunogenicity of an antigen
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
EP1034792A1 (en) * 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
PL355287A1 (en) * 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
EP2545937A1 (en) * 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
CA2457595A1 (en) * 2001-08-16 2003-02-27 Lyfjathroun H.F., Biopharmaceuticals A method of producing antibodies ex-vivo
KR100406503B1 (ko) * 2001-09-25 2003-11-19 한국과학기술연구원 폐렴구균성 표면 접착단백질의 가용화용 조성물, 가용화용액상제형, 및 가용화용 분말제형, 이들 각각의 제조방법및 백신
JP2005519075A (ja) * 2002-02-25 2005-06-30 リフジャスロウン エイチエフ 吸収促進剤
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
ATE544354T1 (de) 2002-11-26 2012-02-15 Univ Chicago Vermeidung und behandlung von mikrobenübertragenen epithelerkrankungen
US9717754B2 (en) 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20070184058A1 (en) * 2003-02-27 2007-08-09 Yaron Ilan Glucocerebroside treatment of pulmonary or respiratory diseases or disorders
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
CA2563533C (en) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
WO2006079989A2 (en) * 2005-01-28 2006-08-03 North-West University Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
EP1871349A1 (en) * 2005-04-11 2008-01-02 Nanobio Corporation Quaternary ammonium halides for treatment of infectious conditions
JP2009504805A (ja) * 2005-08-09 2009-02-05 ナノバイオ コーポレーション 抗炎症活性を有するナノエマルジョン組成物
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US20080038295A1 (en) * 2006-04-13 2008-02-14 Regents Of The University Of Michigan Compositions and methods for orthopox virus vaccination
US9839685B2 (en) * 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
JP5275047B2 (ja) * 2007-01-31 2013-08-28 久光製薬株式会社 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
AU2008279584A1 (en) * 2007-04-27 2009-01-29 Dow Global Technologies Inc. Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
RU2678833C2 (ru) * 2008-09-17 2019-02-04 Киазма Инк. Фармацевтические композиции и соответствующие способы доставки
EP3020412B1 (en) * 2009-06-16 2017-10-11 The Regents of the University of Michigan An immunogenic composition comprising nanoemulsion inactivated rsv
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
ES2744454T3 (es) 2013-10-31 2020-02-25 Hisamitsu Pharmaceutical Co Composición de adyuvante
US10525088B2 (en) 2014-05-30 2020-01-07 Kirin Holdings Kabushiki Kaisha Lactic acid bacterial immunopotentiating activity-increasing composition and method for increasing immunopotentiating activity of lactic acid bacteria
SI3253401T1 (sl) 2015-02-03 2025-07-31 Amryt Endo, Inc. Zdravljenje akromegalije z oralnim oktreotidom
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CN111721937B (zh) * 2019-03-29 2023-04-07 北京九强生物技术股份有限公司 人附睾蛋白4免疫比浊试剂盒
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171125A (en) * 1966-06-08 1969-11-19 Glaxo Lab Ltd Improvements in or relating to Injectable Preparations
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
DE3446515A1 (de) * 1984-12-20 1986-06-26 Behringwerke Ag, 3550 Marburg Oeladjuvierte vaccine und verfahren zu ihrer herstellung
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
NL9000207A (da) * 1990-01-29 1991-08-16 Duphar Int Res
GB9018690D0 (en) * 1990-08-24 1990-10-10 Wellcome Found Vaccines
DE69229779T2 (de) * 1991-04-19 1999-12-23 Lds Technologies, Inc. Konvertierbare mikroemulsionsverbindungen
JP3566284B2 (ja) * 1991-08-26 2004-09-15 ザ スクリップス リサーチ インスティテュート Ｂ型肝炎ウイルスに対する細胞障害性ｔリンパ球の応答を誘発するペプチド類
CA2083553A1 (en) * 1991-11-25 1993-05-26 Kuniharu Seki Immunogen composition

Also Published As

Publication number Publication date
NO953182L (no) 1995-10-12
OA10564A (en) 2002-06-20
US5942237A (en) 1999-08-24
PT682528E (pt) 2001-01-31
EP0682528A1 (en) 1995-11-22
DE69425427T2 (de) 2001-02-08
NO953182D0 (no) 1995-08-14
ES2150982T3 (es) 2000-12-16
EP0682528B1 (en) 2000-08-02
AU6106594A (en) 1994-08-29
ATE195077T1 (de) 2000-08-15
JPH09508614A (ja) 1997-09-02
DK0682528T3 (da) 2000-12-27
NO312057B1 (no) 2002-03-11
AU668290B2 (en) 1996-04-26
DE69425427D1 (de) 2000-09-07
WO1994017827A1 (en) 1994-08-18
CA2156084A1 (en) 1994-08-18
GR3034727T3 (en) 2001-01-31

Similar Documents

Publication Publication Date Title
DK0682528T3 (da) Lægemiddelpræparat til topisk administration af antigener og/eller vacciner til pattedyr via en slimhindemembran
KR950700758A (ko) 비-이온성 계면활성제 소포를 함유하는 백신(Vaccines containing non ionic surfactant vesicles)
ES2113882T3 (es) Vacuna oral que comprende un antigeno asociado superficialmente con eritrocitos.
ATE250937T1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
TR200002930T2 (tr) Kolaylaştırıcı kompozisyonlar
DK0799024T3 (da) Farmaceutisk aerosol indeholdende mindst en sukker
NO982497D0 (no) Vaksine-sammensetninger for inntak gjennom nesen
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
BR0107621A (pt) Sistema de liberação de droga por bombeamento osmótico/ difusão combinados
IT8619675A0 (it) Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale.
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
NO308022B1 (no) Sammensetninger for orale preparater
ES2061252T3 (es) Agente antitusivo y regulador de la mucosa, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
DK0568577T3 (da) Peroralt indgivelig lægemiddelform til behandling af centrale dopaminmangeltilstande
IT8821324A0 (it) Composizioni farmaceutiche ad attivita' analgesica ed antiinfiammatoria per uso orale, dotate di ottima palatabilita' ed esenti da effetti irritanti sulle mucose.
ATE240117T1 (de) Multikomponentenimpfstoff aus clostridien, der saponin als adjuvans benutzt
DE69928806D1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
DK0682950T3 (da) Slimhindeadministration af pneumokok-antigener
FR2682114B1 (fr) Vaccin de sous-unite contre les infections a neisseria meningitidis et sous-unites correspondantes a l'etat purifie.
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
Sanchez et al. Immunological response to Vibrio cholerae O1 infection and an oral cholera vaccine among Peruvians
ES2092559T3 (es) Formulacion farmaceutica que contiene penciclovir.
IT8609514A0 (it) Utilizzazione di ottilonio bromuro (dci) per applicazione topica nel tratto gastro-intestinale e relativa formulazione farmaceutica appropriata per tale uso.
IT1244373B (it) Composizioni farmaceutiche per uso orale contenenti eparina a basso peso molecolare, loro preparazione ed uso
FI981624A7 (fi) Koostumukset ja menetelmät Borrelia burgdorferi antigeenien annostelem iseksi

Legal Events

Date Code Title Description
A0 Application filed
AHS Application shelved for other reasons than non-payment